McKesson Ventures, LLC 4
4 · Augmedix, Inc. · Filed Oct 7, 2020
Insider Transaction Report
Form 4
Augmedix, Inc.NONE
McKesson Ventures, LLC
Director10% Owner
Transactions
- Award
Common Stock
2020-10-05+3,268,440→ 3,268,440 total - Purchase
Common Stock
2020-10-05$3.00/sh+666,666$1,999,998→ 3,935,106 total - Award
Warrant (right to buy)
2020-10-05+303,893→ 303,893 totalExercise: $2.88Exp: 2029-09-02→ Common Stock (303,893 underlying)
Footnotes (3)
- [F1]On October 5, 2020, the Issuer's wholly-owned subsidiary, August Acquisition Corp. ("Acquisition Sub"), merged with and into Augmedix, Inc., a privately held Delaware corporation ("Augmedix"). Pursuant to this transaction (the "Merger"), Augmedix was the surviving corporation and became the Issuer's wholly owned subsidiary. All of the outstanding shares of stock of Augmedix held by accredited investors were converted into shares of the Issuer's common stock. All of the outstanding warrants, options and stock appreciation rights of Augmedix were assumed by the Issuer.
- [F2]These securities are held of record by McKesson Ventures LLC ("McKesson"). Jennifer M. Carter, a member of the Issuer's board of directors, is an executive vice president and chief strategy and business development officer at McKesson. As a result, McKesson is a director by deputization for Section 16 purposes.
- [F3]The warrants are fully vested and exerciseable.